SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059628
Filing Date
2024-05-14
Accepted
2024-05-14 16:29:21
Documents
68
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q kytx-20240331.htm   iXBRL 10-Q 2014210
2 EX-31.1 kytx-ex31_1.htm EX-31.1 14892
3 EX-31.2 kytx-ex31_2.htm EX-31.2 14868
4 EX-32.1 kytx-ex32_1.htm EX-32.1 10594
5 EX-32.2 kytx-ex32_2.htm EX-32.2 10155
  Complete submission text file 0000950170-24-059628.txt   7435844

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kytx-20240331.xsd EX-101.SCH 1006355
72 EXTRACTED XBRL INSTANCE DOCUMENT kytx-20240331_htm.xml XML 1081612
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Filer) CIK: 0001994702 (see all company filings)

IRS No.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41947 | Film No.: 24944866
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)